Rankings
▼
Calendar
XLO Q1 2024 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
XLO
Xilio Therapeutics, Inc.
$28M
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$17M
Net Income
-$17M
EPS (Diluted)
$-0.62
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$11M
Free Cash Flow
-$11M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$83M
Total Liabilities
$57M
Stockholders' Equity
$26M
Cash & Equivalents
$34M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$17M
-$24M
+25.7%
Net Income
-$17M
-$23M
+24.0%
← FY 2024
All Quarters
Q2 2024 →